Yesterday, an FDA panel voted 20 to 1 not to approve Arcoxia for osteoarthritis. Why such an overwhelming number?
Apparently, Arcoxia failed to prove that it served an unmet need. According to Merrill Goozner, Merck took some pretty poor evidence with them to the trial.
Merck stepped forward with an extremely weak set of data. [...]

[Read more →]